CNN Health
Respiratory viruses Vaccines Prescription drugs See all topics Facebook Tweet Email Link Link Copied! Follow
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.
The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck.
The therapy, Enflonsia, is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Related article Bandage after applying vaccine
HuffPost Crime
CNN Politics
National Public Radio
The US Sun Politics
Totalprosports
CBS News